Mutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase the risk of developing
breast cancer (BC) and are found in~ 5% of unselected patients with the disease. BC …

Purpose To conduct a systematic review of international guidelines on screening and
management of patients with BRCA-mutated breast cancer (BC). Methods Major electronic …

Background Population-based estimates of the risk of breast cancer associated with
germline pathogenic variants in cancer-predisposition genes are critically needed for risk …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic provide recommendations for genetic testing and counseling for hereditary …

PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical
genetic testing and results among population-based patients with breast and ovarian …

Background: The cost-effectiveness of screening the US population for Centers for Disease
Control and Prevention (CDC) Tier 1 genomic conditions is unknown. Objective: To estimate …

More than 15 years have passed since the identification, through linkage, of 'first-
wave'susceptibility genes for common cancers (BRCA1, BRCA2, MLH1 and MSH2). These …

Purpose Although the role of CHEK2 germline pathogenic variants in cancer predisposition
is well known, resources for managing CHEK2 heterozygotes in clinical practice are limited …

PURPOSE To determine the sensitivity and specificity of genetic testing criteria for the
detection of germline pathogenic variants in women with breast cancer. MATERIALS AND …

Importance Genomic screening for hereditary breast and ovarian cancer (HBOC) in
unselected women offers an opportunity to prevent cancer morbidity and mortality, but the …